Abstract | INTRODUCTION: PATIENTS AND METHODS: This was a prospective, nonrandomised study in which 26 patients with solid tumours and confirmed bone metastases were treated with ZA (4 mg every 3-4 weeks) for 24 months or until a skeletal-related event (SRE) was observed. Serum CTX levels were determined at baseline and 6, 12, 18 and 24 months after study initiation. SRE were evaluated using bone scintigraphy. RESULTS: Study participants had prostate (50%), breast (31%), lung (11%) or bladder (8%) tumours. Mean age was 69 (range 52-84) years, and 65% men. At baseline, overall mean CTX levels were 562.47 ± 305.17 pg/dl. Patients who showed disease progression during the study period showed significantly higher CTX levels at baseline and after 18 months of ZA treatment than patients who did not progress (p = 0.040 and p = 0.006, respectively). Patients with ≥ 5 bone metastases at diagnosis had significantly higher CTX levels after 18 months of ZA treatment than patients with < 5 bone metastasis (p = 0.001). Similarly, at 12 and 18 months, patients without SRE had significantly lower CTX levels than patients in whom a SRE was observed (p = 0.005 and p = 0.001, respectively). CONCLUSIONS: Changes in serum CTX levels seem to predict the potential for tumour control and the likelihood of developing an SRE in a sample of patients with solid tumours and bone metastases treated with ZA.
|
Authors | María Concepción López-Carrizosa, Pilar María Samper-Ots, Aurora Rodríguez Pérez |
Journal | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
(Clin Transl Oncol)
Vol. 12
Issue 8
Pg. 568-73
(Aug 2010)
ISSN: 1699-3055 [Electronic] Italy |
PMID | 20709654
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- Bone Density Conservation Agents
- Collagen Type I
- Diphosphonates
- Imidazoles
- Peptides
- collagen type I trimeric cross-linked peptide
- Zoledronic Acid
|
Topics |
- Aged
- Aged, 80 and over
- Analysis of Variance
- Biomarkers, Tumor
(blood)
- Bone Density Conservation Agents
(therapeutic use)
- Bone Neoplasms
(metabolism, pathology, secondary)
- Bone and Bones
(pathology)
- Collagen Type I
(blood)
- Diphosphonates
(therapeutic use)
- Disease Progression
- Female
- Fractures, Spontaneous
(pathology)
- Humans
- Imidazoles
(therapeutic use)
- Male
- Middle Aged
- Neoplasms
(pathology)
- Peptides
(blood)
- Prognosis
- Prospective Studies
- Statistics, Nonparametric
- Zoledronic Acid
|